ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 83

The Risk of Developing Rheumatoid Arthritis Based on HLA-DQ Genotypes

Sami B. Kanaan1, Oyku Sensoy2 and J. Lee Nelson3, 1Clinical Research Division, Fred Hutchinson Cancer Research Center, SEATTLE, WA, 2Clinical Research Division, Fred Hutchinson Cancer Research Center, seattle, WA, 3Fred Hutchinson Cancer Research Center, Seattle, WA

Meeting: 2018 ACR/ARHP Annual Meeting

Keywords: human leukocyte antigens (HLA), rheumatoid arthritis (RA) and risk

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Sunday, October 21, 2018

Title: Rheumatoid Arthritis – Etiology and Pathogenesis Poster I

Session Type: ACR Poster Session A

Session Time: 9:00AM-11:00AM

Background/Purpose: The strongest genetic risk for rheumatoid arthritis (RA) is contributed from the HLA region. RA-risk associated HLA-DRB1 alleles including *04:01/4/5/8, *01:01, *10:01, and *14:02 code for the ‘Shared Epitope’ (SE) motif of the DRβ1 third hypervariable region. In an individual’s genotype, different combinations of SE and non-SE alleles contribute differently to RA-risk, as has been delineated in a table of Odds Ratios (OR) in a prior publication (1). Other studies have pointed to the importance in RA of specific DQA1‒DQB1 allele combinations in linkage disequilibrium (LD) with SE alleles that have been referred to as DQ5.1, DQ7.3, and DQ8 (2, 3). Interestingly, these particular DQ molecules, but not other DQs or DRs, bind certain peptides involved in autoantibody-positive RA (3). In the current study we investigated RA risk according to the DQ genotype and evaluated combinations of DQ molecules for hierarchy in RA risk.

Methods: 314 RA patients meeting 1988 ACR criteria and 316 controls from Washington State (USA) and the surrounding area were genotyped for DRB1‒DQA1‒DQB1 haplotypes. DQA1 and DQB1 combinations were classified into 10 groups based on functional relevance and most frequent LD with DRB1: DQ5.1 (LD: DRB1*01), DQ5.2/3 (LD: DRB1*14 and *16), DQ6.1/2 (LD: DRB1*15), DQ6.3/4/5/9 (LD: DRB1*13, RA protective), DQ2 (LD: DRB1*03 and *07, both RA protective), DQ7.3 (LD: DRB1*04), DQ7.5/6 (LD: DRB1*11 and *12), DQ8 (LD: DRB1*04), DQ9 (LD: DRB1*07 and *09), and DQ4 (LD: DRB1*08). ORs for RA-risk were calculated for 48 of 55 possible combinations accounting for 97% of subjects.

Results: The genotypic OR [and 95% confidence intervals] for developing RA based on DQ ranged from 24.9 [4.63‒259.0] to 0.16 [0.04‒0.64]. The risk was generally significant when an individual carried simultaneously 2 of the 3 DQs in linkage with the SE (DQ5.1, DQ7.3 and DQ8), and was alleviated when the second DQ was no longer of those 3. DQ2 provided significant protection when combined with itself, DQ6.3/4/5/9, or DQ7.5/6, which are in linkage with DRB1 alleles previously associated with protection against RA.

Conclusion: The risk of developing RA is influenced by both HLA-DQ alleles in the genotype. ORs varied according to particular combinations of DQ molecules. These observations considered along with recognition that HLA molecules present peptides derived from other (self) HLA molecules point to likely functional significance of HLA-DQ molecules in RA risk.

References:

  1. N. Balandraud et al., PLOS ONE. 8, e64108 (2013).
  2. E. Zanelli, C. J. Krco, J. M. Baisch, S. Cheng, C. S. David, PNAS. 93, 1814–1819 (1996).
  3. J. van Heemst et al., Nature Communications. 6, 6681 (2015).

Funding: This work was supported by NIH grants HL117737 and AI 45659.


Disclosure: S. B. Kanaan, None; O. Sensoy, None; J. L. Nelson, None.

To cite this abstract in AMA style:

Kanaan SB, Sensoy O, Nelson JL. The Risk of Developing Rheumatoid Arthritis Based on HLA-DQ Genotypes [abstract]. Arthritis Rheumatol. 2018; 70 (suppl 9). https://acrabstracts.org/abstract/the-risk-of-developing-rheumatoid-arthritis-based-on-hla-dq-genotypes/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to 2018 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/the-risk-of-developing-rheumatoid-arthritis-based-on-hla-dq-genotypes/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology